ica 1

ICA 110381 is a KCNQ2 Q3 potassium channel opener for the treatment of epilepsy

CRT0044876 (7-NO2-ICA) is a potent and selective APE1 inhibitor with IC50 of ~3 μM.

ICA-105665 (PF-04895162) is a potent and orally active opener of neuronal Kv7.2 7.3 and Kv7.3 7.5 potassium channels. ICA-105665 had low cytotoxic potential in human hepatocytes but inhibited liver mitochondrial function and bile salt export protein (BSEP) transport (IC50 of 311 μM). ICA-105665 can penetrate the central nervous system (CNS) and has antiseizure effects [1][2][3][4].

DL-threo-2-methylisocitrate is a substrate of isocitrate lyase 1 (ICL1). Using Michaelis-Menten nonlinear least squares fitting, the kcat value was 1.25 s-1 and the Km was 718 μM. In comparison, the Km of threonine-D(s)L(s)-isocitrate (ICA) was 188 μM and the kcat was 5.24 s-1.

dl-threo-2-methylisocitrate is a substrate of isocitrate lyase 1 (ICL1). IC50 value: target: using michael-menten nonlinear least squares fitting to determine the purified recombinant ICL1's Km for threo-D(s)L(s)-isocitrate (ICA) is 188°M and kcat is 5.24

MMPI-1154 is a highly promising imidazole-carboxylic acid (ICA) MMP-2 inhibitor (IC 50 = 6.6 μM) with excellent cardio-cytoprotective properties. It is specifically designed for the study of acute myocardial infarction. Additionally, MMPI-1154 exhibits significant inhibitory effects on MMP-13, MMP-1, and MMP-9 activities with IC 50 values of 1.8 μM, 10 μM, and 13 μM, respectively.

Sulcardine, a multi-ion channel blocker, reduces I Na and I Ca with IC 50 values of 26.9 µmol L and 69.2 µmol L, respectively. It has anti-arrhythmic effects [1].